Research Paper Volume 12, Issue 24 pp 25275—25293
DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications
Figure 9. Correlations between the methylation model and clinical characteristics. (A) The prognostic model. (B) Nomogram for predicting the probability of 1-, 3-, and 5-year overall survival of patients with LUAD. (C) The recurrent model. (D) Nomogram for predicting the probability of 1-, 3-, and 5-year disease-free survival of patients with LUAD. LUAD, lung adenocarcinoma.